Patents Assigned to The Johns Hopkins Univ.
-
Patent number: 7101865Abstract: The present invention provides novel sulfoximine compounds, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the compounds of the invention are useful for treating diseases which benefit from a modulation of the levels of 1?,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.Type: GrantFiled: June 13, 2003Date of Patent: September 5, 2006Assignees: Cytochroma Inc., Johns Hopkins Univ.Inventors: Gary H. Posner, Mehmet Kahraman, Uttam Saha
-
Patent number: 6316003Abstract: This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which include HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation.Type: GrantFiled: April 28, 1994Date of Patent: November 13, 2001Assignees: Whitehead Institute for Biomedical Research, Johns Hopkins Univ. School of Medicine, Biogen, Inc.Inventors: Alan Frankel, Carl Pabo, James G. Barsoum, Stephen E. Fawell, R. Blake Pepinsky
-
Patent number: 5912225Abstract: Biodegradable polymers are described comprising the recurring monomeric units shown in formula I: ##STR1## wherein: R is selected from the group consisting of H, alkyl, aryl or heterocyclic; andR' is selected from the group consisting of H, alkyl, alkoxy, aryl, aryloxy, heterocyclic or heterocycloxy; andn is 5 to 500,wherein said biodegradable polymer is biocompatible before and upon biodegradation.Processes for preparing the polymers, compositions containing the polymers and biologically active substances, articles useful for implantation or injection into the body fabricated from the compositions, and methods for controllably releasing biologically active substances using the polymers, are also described.Type: GrantFiled: April 14, 1997Date of Patent: June 15, 1999Assignee: Johns Hopkins Univ. School of MedicineInventors: Hai-quan Mao, Kam W. Leong
-
Patent number: 5760259Abstract: A method of inhibiting parasitic activity is disclosed in which the biosynthesis, structure and/or function of the glycotyl phosphatidylinositol (GPI) anchor of said parasite may be affected by incorporating into said GPI anchor selected analogs of myristic acid containing various heteroatoms, substituents and unsaturated bonds, including ester-containing analogs, ketocarbonyl-containing analogs, sulfur-containing analogs, double bond- and triple bond-containing analogs, aromatic moiety-containing analogs, nitrated analogs and halogenated analogs.Type: GrantFiled: March 18, 1996Date of Patent: June 2, 1998Assignees: Washington University, Johns Hopkins Univ.Inventors: Jeffrey I. Gordon, George W. Gokel, Paul T. Englund
-
Patent number: 5696135Abstract: This invention relates to the method of using neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity to stimulate or promote neuronal growth or regeneration.Type: GrantFiled: May 28, 1996Date of Patent: December 9, 1997Assignees: GPI NIL Holdings, Inc., Johns Hopkins Univ. School of MedicinesInventors: Joseph P. Steiner, Solomon Snyder, Gregory S. Hamilton
-
Patent number: 5505955Abstract: An anti-diarrheic product comprises a foodstuff and an anti-rotaviral agent such as human defatted fat globule membranes, the human milk macromolecular fraction, the milk mucin complex, the 46 Kd apparent MW glycoprotein, a polypeptide having the rotavirus-binding specificity of the 46 Kd apparent MW HMFG glycoprotein, mixtures thereof, or mixtures thereof, and optionally skim milk, curd, and/or whey. They product of the invention is provided also as an anti-diarrheal kit, with instructions for its use. The product of the invention has therapeutic and prophylactic application for inhibiting the onset of, or countering, rotavirus infection and/or diarrhea, in a subject, such as for example, infants and children (infantile gasteroenteritis), travellers, and immunodeficient persons, including HIV positive and transplant patients.Type: GrantFiled: January 23, 1995Date of Patent: April 9, 1996Assignees: Senomed, Inc., Cancer Research Fund of Contra Costa, The Johns Hopkins Univ. School of MedicineInventors: Jerry A. Peterson, Robert H. Yolken, David S. Newburg
-
Patent number: 5352775Abstract: A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC is expressed in most normal tissues. These results suggest that APC is a tumor suppressor.Type: GrantFiled: August 8, 1991Date of Patent: October 4, 1994Assignees: The Johns Hopkins Univ., The Univ. of Utah, Imperial Chemical Industries, Cancer InstituteInventors: Hans Albertsen, Rakesh Anand, Mary Carlson, Joanna Groden, Philip J. Hedge, Geoff Joslyn, Kenneth Kinzler, Alexander F. Markham, Yusuke Nakamura, Andrew Thliveris, Bert Vogelstein, Raymond L. White
-
Patent number: 5234680Abstract: The present invention is directed to biological compounds derivatized so as to contain at least one perfluoro-t-butyl moiety for use in fluorine-19 NMR and/or MRI studies. The perfluoro-t-butyl (PFTB) moiety, ##STR1## is an excellent reporter group for fluorine-19 NMR/MRI. It is a source of nine magnetically equivalent fluorine nuclei which generate a single intense resonance for easy detection in spectroscopy or imaging. This signal is a sharp singlet, not split by neighboring nuclei or spread over a wide frequency range and eliminates any chance of ghost images which might arise from multiple resonances. These spectral properties ensure a maximum signal-to-noise ratio (S/N) for readily detecting this moiety. The foregoing allows either reduction in the concentration of the derivatized compound, ability to use MRI instruments with lower field strengths, a reduction in imaging times, or a combination of the foregoing as a result of this moiety producing a single, sharp, intense resonance.Type: GrantFiled: September 19, 1991Date of Patent: August 10, 1993Assignees: Johns Hopkins Univ., Towson State UniversityInventors: Walter J. Rogers, Jr., Thomas S. Everett
-
Patent number: 5116599Abstract: Accordingly, the present invention is directed to biological compounds derivatized so as to contain at least one perfluoro-t-butyl moiety for use in fluorine-19 NMR and/or MRI studies. The perfluoro-t-butyl (PFTB) moiety, ##STR1## is an excellent reporter group for fluorine-19 NMR/MRI. It is a source of nine magnetically equivalent fluorine nuclei which generate a single intense resonance for easy detection in spectroscopy or imaging. This signal is a sharp singlet, not split by neighboring nuclei or spread over a wide frequency range and eliminates any chance of ghost images which might arise from multiple resonances. These spectral properties ensure a maximum signal-to-noise ratio (S/N) for readily detecting this moiety. The foregoing allows either reduction in the concentration of the derivatized compound, ability to use MRI instruments with lower field strengths, a reduction in imaging times, or a combination of the foregoing as a result of this moiety producing a single, sharp, intense resonance.Type: GrantFiled: July 31, 1989Date of Patent: May 26, 1992Assignees: Johns Hopkins Univ., Towson State Univ.Inventors: Walter J. Rogers, Jr., Thomas S. Everett
-
Patent number: 4936823Abstract: An implant capsule for insertion into a body canal to apply radiation treatment to a selected portion of the body canal. The device includes a body member defining at least one therapeutic treatment material receiving chamber and at least one resilient arm member associated with the body member for removably engaging the body canal when the device is positioned therein.Type: GrantFiled: May 4, 1988Date of Patent: June 26, 1990Assignees: Triangle Research and Development Corp., The Johns Hopkins Univ.Inventors: David P. Colvin, Bernard R. Marsh